<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04800497</url>
  </required_header>
  <id_info>
    <org_study_id>FINDINGBIOREC</org_study_id>
    <nct_id>NCT04800497</nct_id>
  </id_info>
  <brief_title>The Role Of Circulating Tumor Cells As Markers Of Advanced Disease And Prognosis In HCC</brief_title>
  <official_title>Finding The Seeds Of Recurrence: The Role Of The Liquid Biopsy To Detect Circulating Tumor Cells As Markers Of Advanced Disease And Prognosis In HCC</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Milano Bicocca</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Università degli Studi del Piemonte Orientale &quot;Amedeo Avogadro&quot;</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Niguarda Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Humanitas Clinical and Research Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Azienda Ospedaliero Universitaria Maggiore della Carita</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Milano Bicocca</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hepatocellular carcinoma (HCC) recurs in up to 60% of patients who undergo resection.&#xD;
      Circulating tumor cells (CTC) have been advocated as promotors of the recurrence. However,&#xD;
      their role as prognostic markers in the surgical setting is unclear. The aim of the present&#xD;
      study has been to assess the association between CTC from peripheral blood samples and the&#xD;
      risk of recurrence after surgery.&#xD;
&#xD;
      Patients with a first diagnosis of HCC, no previous treatment for this condition, no other&#xD;
      oncological history, and BCLC stage 0-A-B will be enrolled in 2 centers. Patients will&#xD;
      undergo to serial liquid biopsies (i.e., a 15ml peripheral blood sample on each time point)&#xD;
      at day 0-30-90-180-365 after surgery. After isolation of peripheral blood mononucleate cells,&#xD;
      CTC will be detected by FACSymphony™ and subsequently the following markers will be&#xD;
      identified: EpCAM, N-cadherin (N-cad) and CD90. Epithelial-mesenchymal transition (EMT) will&#xD;
      be analyzed by an index estimated as the ratio between the number of EpCAM+/N-cad- and&#xD;
      EpCAM+/N-cad+ cells (EMT Index). Patients will be divided according to the recurrence status.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 7, 2019</start_date>
  <completion_date type="Anticipated">February 7, 2024</completion_date>
  <primary_completion_date type="Anticipated">February 7, 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Association between circulating tumor cells and disease-free-survival</measure>
    <time_frame>5 years</time_frame>
    <description>To evaluate the association between variation in CTCs - determined in blood samples - and disease-free-survival in HCC patients after surgery.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Association between circulating tumor cells and overall survival</measure>
    <time_frame>5 years</time_frame>
    <description>To evaluate the association between variation in CTCs - determined in blood samples - and overall survival in HCC patients after surgery.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <condition>Recurrent Hepatocellular Carcinoma</condition>
  <condition>Circulating Tumor Cell</condition>
  <arm_group>
    <arm_group_label>Patients resected for hepatocellular carcinoma</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients who underwent surgery for benign diseases</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Hepatic resection</intervention_name>
    <description>Hepatic resection for HCC</description>
    <arm_group_label>Patients resected for hepatocellular carcinoma</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Planned number of subjects to be screened for resection group: almost 40 per year (patients&#xD;
        treated/year in centres already registered as participating). Final number of enrolled at&#xD;
        the end of the period: 80 patients. Planned number of subjects to be screened for OLT&#xD;
        group: almost 30 per year. Final number of enrolled at the end of the period: 60 patients.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Hepatocarcinoma diagnosis confirmed by radiology and committed to surgery (resection&#xD;
             or OLT) with curative intent.&#xD;
&#xD;
          -  First diagnosis and first treatment of hepatocellular carcinoma.&#xD;
&#xD;
          -  BCLC 0 - A - B&#xD;
&#xD;
          -  Histological confirmation of hepatocarcinoma at the histological specimen.&#xD;
&#xD;
          -  Availability of a fresh frozen section of the tumor obtained during the surgical&#xD;
             procedures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Other tumors in the clinical history.&#xD;
&#xD;
          -  Presence of autoimmune liver diseases (eg. sclerotising cholangitis, primary biliary&#xD;
             cirrhosis etc.).&#xD;
&#xD;
          -  Patients treated with surgery in case of not-curative intent (palliation, best&#xD;
             supportive care, etc).&#xD;
&#xD;
          -  Histopathological specimen of combined liver primary neoplasms (e.g.&#xD;
             'epatocolangiocarcinoma').&#xD;
&#xD;
          -  Patients previously treated for HCC with other therapies&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Simone Famularo</last_name>
    <phone>+39 3296533353</phone>
    <email>simone.famularo@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Cristina Ciulli</last_name>
    <phone>+39 3896460025</phone>
    <email>cri.ciulli@hotmail.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ospedale San Gerardo</name>
      <address>
        <city>Monza</city>
        <state>MB</state>
        <zip>20900</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fabrizio Romano</last_name>
    </contact>
    <investigator>
      <last_name>Fabrizio Romano</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cristina Ciulli</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Francesca Carissimi</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Linda Roccamatisi</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Giuseppe Cordaro</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Biagio Eugenio Leone</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ASST Grande Ospedale Metropolitano Niguarda</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Lauterio, MD</last_name>
    </contact>
    <investigator>
      <last_name>Luciano De Carlis</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andrea Lauterio</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Università del Piemonte Orientale</name>
      <address>
        <city>Novara</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rosalba Minisini</last_name>
    </contact>
    <investigator>
      <last_name>Mario Pirisi</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rosalba Minisini</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Matteo Nazzareno Barbaglia</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Livia Salmi</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Venkata Ramana Mallela</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Humanitas Research Hospital</name>
      <address>
        <city>Rozzano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Simone Famularo, MD, PhD</last_name>
      <email>simone.famularo@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Guido Torzilli</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Matteo Donadon</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Simone Famularo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>February 22, 2021</study_first_submitted>
  <study_first_submitted_qc>March 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 16, 2021</study_first_posted>
  <last_update_submitted>March 12, 2021</last_update_submitted>
  <last_update_submitted_qc>March 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Milano Bicocca</investigator_affiliation>
    <investigator_full_name>Fabrizio Romano</investigator_full_name>
    <investigator_title>Prof. Fabrizio Romano</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Neoplastic Cells, Circulating</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

